Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
71.21 USD | +0.10% |
|
+0.15% | -14.05% |
Apr. 11 | Truist Trims Price Target on Globus Medical to $80 From $82, Keeps Hold Rating | MT |
Apr. 03 | Globus Medical Closes Acquisition of Nevro | MT |
Capitalization | 9.78B 8.61B 7.99B 7.4B 13.58B 838B 15.32B 95.63B 36.87B 373B 36.72B 35.94B 1,397B | P/E ratio 2025 * |
24.9x | P/E ratio 2026 * | 21.4x |
---|---|---|---|---|---|
Enterprise value | 9.1B 8.01B 7.43B 6.88B 12.64B 780B 14.26B 88.99B 34.31B 347B 34.16B 33.44B 1,300B | EV / Sales 2025 * |
3.35x | EV / Sales 2026 * | 2.93x |
Free-Float |
82.69% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Globus Medical, Inc.
1 day | +0.60% | ||
1 week | +0.55% | ||
Current month | -2.50% | ||
1 month | -1.07% | ||
3 months | -21.40% | ||
6 months | -3.45% | ||
Current year | -13.71% |







Manager | Title | Age | Since |
---|---|---|---|
Daniel Scavilla
CEO | Chief Executive Officer | 60 | 2022-04-20 |
Keith Pfeil
DFI | Director of Finance/CFO | 46 | 2019-08-18 |
Brian Kearns
IRC | Investor Relations Contact | - | - |
Director | Title | Age | Since |
---|---|---|---|
David Paul
CHM | Chairman | 58 | 2003-02-28 |
David Davidar
BRD | Director/Board Member | 59 | 2003-02-28 |
Daniel Lemaitre
BRD | Director/Board Member | 71 | 2011-04-20 |
Name | Weight | AuM | 1st Jan change | |
---|---|---|---|---|
1.01% | 3 M€ | -10.24% | - | |
0.99% | 123 M€ | -16.84% | - | |
0.44% | 6 M€ | 0.00% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+0.46% | +0.55% | +39.39% | -6.49% | 9.78B | ||
+0.24% | +5.42% | +23.94% | +12.86% | 225B | ||
-0.21% | +0.28% | +4.67% | -23.42% | 106B | ||
-0.31% | -0.02% | -14.26% | -23.46% | 57.54B | ||
+0.02% | +1.92% | +19.23% | +75.73% | 55.16B | ||
+0.82% | -1.03% | -12.40% | +21.72% | 36.76B | ||
+3.22% | -5.30% | +4.29% | +43.51% | 27.1B | ||
-1.03% | +1.75% | -48.84% | -43.01% | 26.95B | ||
+0.96% | +1.94% | +10.54% | -8.50% | 21.62B | ||
-3.29% | +17.84% | -25.60% | -45.18% | 21.15B | ||
Average | +0.07% | +2.42% | +0.10% | +0.38% | 58.71B | |
Weighted average by Cap. | +0.04% | +1.37% | +7.73% | +4.86% |
2025 * | 2026 * | |
---|---|---|
Net sales | 2.71B 2.39B 2.22B 2.05B 3.77B 232B 4.25B 26.53B 10.23B 104B 10.19B 9.97B 388B | 2.91B 2.56B 2.37B 2.2B 4.04B 249B 4.55B 28.42B 10.96B 111B 10.91B 10.68B 415B |
Net income | 398M 350M 325M 301M 552M 34.06B 623M 3.89B 1.5B 15.17B 1.49B 1.46B 56.8B | 466M 410M 380M 352M 647M 39.89B 730M 4.55B 1.76B 17.77B 1.75B 1.71B 66.53B |
Net Debt | -680M -598M -555M -514M -944M -58.21B -1.06B -6.65B -2.56B -25.93B -2.55B -2.5B -97.07B | -1.26B -1.11B -1.03B -949M -1.74B -108B -1.97B -12.27B -4.73B -47.88B -4.71B -4.61B -179B |
Date | Price | Change | Volume |
---|---|---|---|
25-04-17 | 71.18 $ | +0.06% | 219,297 |
25-04-16 | 71.14 $ | -1.67% | 800,863 |
25-04-15 | 72.35 $ | -0.86% | 763,370 |
25-04-14 | 72.98 $ | +0.54% | 944,400 |
25-04-11 | 72.59 $ | +2.27% | 1,158,622 |
Delayed Quote Nyse, April 17, 2025 at 10:01 am EDT
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GMED Stock